| Project/Area Number |
26461949
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | National Hospital Organization, Kyushu Cancer Center (2015-2016)
Kyushu University (2014) |
|---|
Principal Investigator |
Tokunaga Eriko 独立行政法人国立病院機構(九州がんセンター臨床研究センター), その他部局等, 乳腺科部長 (50325453)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
岡野 慎士 九州大学, 医学研究院, 准教授 (10380429)
北尾 洋之 九州大学, 医学研究院, 准教授 (30368617)
山下 奈真 九州大学, 医学研究院, 助教 (60608967)
佐伯 浩司 九州大学, 医学研究院, 准教授 (80325448)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 乳癌 / DNA修復 / 遺伝子変異 / 染色体不安定性 / APOBEC3B / ER陽性乳癌 / 癌抑制遺伝子 / サブタイプ |
|---|
| Outline of Final Research Achievements |
Extent of the genomic alterations and loss of heterozygosity (LOH) at tumor suppressor gene (TSG) loci was quite different among subtypes in the primary breast cancer. Low-grade hormone receptor (HR)-positive/HER2 negative subtype has significantly less genomic alterations and LOH at TSG loci compared with other subtypes. HER2 type and triple negative (TN) type have extensive genomic and chromosomal alterations and LOH. In these subtypes, cytotoxic chemotherapy is often used. Some tumors with high genomic alterations are sensitive to chemotherapy, thus genomic abnormalities are not always associated with poor prognosis in HER2 and TN subtypes. On the other hand, in HR-positive/HER2 negative subtype, high genomic alterations are significantly associated with poor prognosis. It suggests that tumors with high genomic alterations are probably resistant to endocrine treatment, which may lead to unfavorable outcomes.
|
